Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus
- 842 Downloads
The incidence of type 2 diabetes mellitus (T2DM) among children and adolescents has been rising. This condition is associated with obesity, and it's prevalence is higher among minority or female youth. Lifestyle modification including diet and exercise is only successful in a small proportion of patients; therefore, pharmacotherapy approaches are needed to treat T2DM among youth. Currently, in the USA, only metformin and insulin are approved for the treatment of T2DM in children. However, several antihyperglycemic agents including exenatide, glimepiride, glyburide, liraglutide, pioglitazone, and rosiglitazone are also used off-label in this population. Moreover, a number of clinical trials are ongoing that are aimed at addressing the safety and efficacy of newer antihyperglycemic agents in this population. Little is known about the safety, efficacy, or pharmacokinetics of antihyperglycemic agents in children or adolescents. Our ability to predict the pharmacokinetics of these agents in youth is hampered first by the lack of information about the expression and activity of drug-metabolizing enzymes and transporters in this population and second by the presence of comorbid conditions such as obesity and fatty liver disease. This article reviews the prevalence of obesity and T2DM in children and adolescents (youth). We then summarize published studies on safety and effectiveness of antihyperglycemic medications in youth. Drug disposition may be affected by age or puberty and thus the expression and activity of different pathways for drug metabolism and xenobiotic transporters are compared between youth and adults followed by a summary of pharmacokinetics studies of antihyperglycemic agents currently used in this population.
KeywordsMetformin Rosiglitazone Pioglitazone Liraglutide Exenatide
Use of the University of Washington Drug Interaction Database is gratefully acknowledged.
Compliance with Ethical Standards
Support received from Grant # R15 GM101599 from the National Institutes of Health is gratefully acknowledged.
Conflicts of interest
Fatemeh Akhlaghi, Kelly L. Matson, Amir Hooshang Mohammadpour, Meghan Kelly, and Asieh Karimani declare that they have no conflicts of interest.
- 32.International Diabetes Federation. Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence. 2011. http://c.ymcdn.com/sites/www.ispad.org/resource/resmgr/Docs/ispadlfac-pocketbook-final.pdf. Accessed Oct 2016.
- 43.Group TS, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24):2247–56.Google Scholar
- 44.Food and Drug Administration of the United States. Statistical Review and Evaluation, Clinical Studies (Glucovance); 2004. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM445509.pdf. Accessed Oct 2016.
- 46.Klein DJ, Battelino T, Chatterjee D, Jacobsen LV, Hale PM, Arslanian S. Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol Ther. 2014;16(10):679–87.CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Dostalek M, Court MH, Hazarika S, Akhlaghi F. Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011;39(3):448–55.CrossRefPubMedPubMedCentralGoogle Scholar
- 68.Prasad B, Gaedigk A, Vrana M, Gaedigk R, Leeder JS, Salphati L, et al. Ontogeny of hepatic drug transporters as quantified by LC-MS/MS proteomics. Clin Pharmacol Ther. 2016;100(4):362–70.Google Scholar
- 74.Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. Clin Ther. 2009;31(4):806–15.CrossRefPubMedGoogle Scholar
- 81.Novo Nordisk A/S. Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetes (Ellipse™). [ClinicalTrials.gov identifier: NCT01541215]. US National Institutes of Health, ClinicalTrials.gov. https://www.clinicaltrials.gov. Accessed 19 Oct 2016.
- 82.AstraZeneca. Safety and efficacy study of exenatide once weekly in adolescents with type 2 diabetes. [ClinicalTrials.gov identifier: NCT01554618]. US National Institutes of Health, ClinicalTrials.gov. https://www.clinicaltrials.gov. Accessed 19 Oct 2016.